Antiemetics and cardiac effects potentially linked to prolongation of the QT interval: Case/non-case analysis in the national pharmacovigilance database;Antiémétiques et effets cardiaques potentiellement liés à un allongement de l'intervalle QT : analyse cas/non-cas dans la Base nationale de pharmacovigilance

Revue d'Epidemiologie et de Sante Publique

Volumn 65, Issue 1, 2017, Pages 1-8

  Rochoy, M ^a,b   Auffret, M ^b,c   Bene J ^b,c   Gautier, S ^b,c  

^a UNIV LILLE   (France)

^b CHU Lille   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Antiemetics; Cardiac arrhythmias; Domperidone; Metopimazine; Sudden death

Indexed keywords

ANTIEMETIC AGENT; DOMPERIDONE; GRANISETRON; METHADONE; METOPIMAZINE; ONDANSETRON; PARACETAMOL;

ARTICLE; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; FAINTNESS; FRANCE; HEART VENTRICLE ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; QT PROLONGATION; SUDDEN CARDIAC DEATH; TORSADE DES POINTES; ADOLESCENT; ADULT; AGED; ARRHYTHMIAS, CARDIAC; BRUGADA SYNDROME; CHEMICALLY INDUCED; DEATH, SUDDEN, CARDIAC; FACTUAL DATABASE; FEMALE; LONG QT SYNDROME; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; TORSADES DE POINTES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ARRHYTHMIAS, CARDIAC; BRUGADA SYNDROME; DATABASES, FACTUAL; DEATH, SUDDEN, CARDIAC; DOMPERIDONE; FEMALE; FRANCE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; PHARMACOVIGILANCE; RETROSPECTIVE STUDIES; TORSADES DE POINTES; YOUNG ADULT;

EID: 85007613409     PISSN: 03987620     EISSN: 17730627     Source Type: Journal    
DOI: 10.1016/j.respe.2016.06.335     Document Type: Article

References (41)

1. [1] Pariente, A., Nausées et vomissements : du symptôme au diagnostic. EMC Traité Médecine AKOS, 2011, Elsevier Masson, Paris, 1–4.
2. [2] Agence nationale de sécurité du médicament et des produits de santé (ANSM), Ventes de médicaments en France : le rapport d'analyse de l'année 2013 [Internet]. 2014 Disponible sur : http://ansm.sante.fr/S-informer/Actualite/Ventes-de-medicaments-en-France-le-rapport-d-analyse-de-l-annee-2013-Communique [cité 28 juillet 2014].
3. [3] Johannes, C.B., Varas-Lorenzo, C., McQuay, L.J., Midkiff, K.D., Fife, D., Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf 19:9 (2010), 881–888.
4. [4] Straus, S.M.J.M., Sturkenboom, M.C.J.M., Bleumink, G.S., Dieleman, J.P., van der Lei, J., de Graeff, P.A., et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 26:19 (2005), 2007–2012.
5. [5] Claassen, S., Zünkler, B.J., Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology 74:1 (2005), 31–36.
6. [6] Hondeghem, L.M., Domperidone: limited benefits with significant risk for sudden cardiac death. J Cardiovasc Pharmacol 61:3 (2013), 218–225.
7. [7] Osborne, R.J., Slevin, M.L., Hunter, R.W., Hamer, J., Cardiotoxicity of intravenous domperidone. Lancet, 326(8451), 1985, 385.
8. [8] Agence nationale de sécurité du médicament et des produits de santé (ANSM), Médicaments contenant de la diacéréine (Art 50 et génériques), médicaments contenant de la dompéridone (Motilium, Peridys et génériques), médicaments à base de zolpidem (Stilnox et génériques), médicaments utilisés dans le double blocage du système rénine [Internet]. 2014 Disponible sur : http://ansm.sante.fr/S-informer/Travaux-de-l-Agence-Europeenne-des-Medicaments-EMA-Comite-pour-l-evaluation-des-risques-en-matiere-de-pharmacovigilance-PRAC/Medicaments-contenant-de-la-diacereine-Art-50-et-generiques-medicaments-contenant-de-la-domperidone-Motilium-Peridys-et-generiques-medicaments-a-base-de-zolpidem-Stilnox-et-generiques-medicaments-utilises-dans-le-double-blocage-du-systeme-renine-angiotensine-bromocriptine-dans-l-inhibition-de-la-lactation-Point-d-information [cité 28 juillet 2014].
9. [9] Agence nationale de sécurité du médicament et des produits de santé (ANSM), De nouvelles recommandations pour minimiser les risques cardiaques des médicaments contenant de la dompéridone [Internet]. 2014 Disponible sur : http://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/De-nouvelles-recommandations-pour-minimiser-les-risques-cardiaques-des-medicaments-contenant-de-la-domperidone-Point-d-Information [cité 3 septembre 2014].
10. [10] Siddique, S.M., Shariff, N., Vesuwala, N., Hafiz, T., Metoclopramide as a possible cause of prolonged QT syndrome and torsade de pointes in a patient with heart failure and renal insufficiency. Ann Intern Med 150:7 (2009), 502–504.
11. [11] Kim, K.-S., Kim, E.-J., The phenothiazine drugs inhibit hERG potassium channels. Drug Chem Toxicol 28:3 (2005), 303–313.
12. [12] Owczuk, R., Twardowski, P., Dylczyk-Sommer, A., Wujtewicz, M.A., Sawicka, W., Drogoszewska, B., et al. Influence of promethazine on cardiac repolarisation: a double-blind, midazolam-controlled study. Anaesthesia 64:6 (2009), 609–614.
13. [13] Moore, N., Kreft-Jais, C., Haramburu, F., Noblet, C., Andrejak, M., Ollagnier, M., et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol 44:5 (1997), 513–518.
14. [14] Egberts, A.C.G., Meyboom, R.H.B., van Puijenbroek, E.P., Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf Int J Med Toxicol Drug Exp 25:6 (2002), 453–458.
15. [15] Montastruc, J.-L., Sommet, A., Bagheri, H., Lapeyre-Mestre, M., Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 72:6 (2011), 905–908.
16. [16] Brown, E.G., Wood, L., Wood, S., The medical dictionary for regulatory activities (MedDRA). Drug Saf Int J Med Toxicol Drug Exp 20:2 (1999), 109–117.
17. [17] Dangoumau, J., Evreux, J.C., Jouglard, J., [Method for determination of undesirable effects of drugs]. Therapie 33:3 (1978), 373–381.
18. [18] Bégaud, B., Evreux, J.C., Jouglard, J., Lagier, G., [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France]. Therapie 40:2 (1985), 111–118.
19. [19] Brown, E.G., Using MedDRA: implications for risk management. Drug Saf Int J Med Toxicol Drug Exp 27:8 (2004), 591–602.
20. [20] Agence nationale de sécurité du médicament et des produits de santé (ANSM), Rupture de stock de VOGALENE (métopimazine) [Internet]. 2014 Disponible sur : http://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Rupture-de-stock-de-VOGALENE-metopimazine-Point-d-Information [cité 28 juillet 2014].
21. [21] Rothman, K.J., Lanes, S., Sacks, S.T., The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13:8 (2004), 519–523.
22. [22] Ban, T.A., Stjean, A., The effect of phenothiazines on the electrocardiogram. Can Med Assoc J 91 (1964), 537–540.
23. [23] Trojak, B., Pinoit, J.-M., André, D., Bonin, B., Gisselmann, A., [Antipsychotic drugs and cardiovascular safety: need for monitoring the QT interval]. Presse Med 35:4 Pt 2 (2006), 699–704.
24. [24] The University of Arizona Center for Education and Research on Therapeutics, Drugs that prolong the QT interval and/or induce torsades de pointes ventricular arrhythmia [Internet]. 2014 Disponible sur : https://www.crediblemeds.org/everyone/composite-list-all-qtdrugs/ [cité 29 juillet 2014].
25. [25] Hennessy, S., Leonard, C.E., Newcomb, C., Kimmel, S.E., Bilker, W.B., Cisapride and ventricular arrhythmia. Br J Clin Pharmacol 66:3 (2008), 375–385.
26. [26] Rampe, D., Roy, M.-L., Dennis, A., Brown, A.M., A mechanism for the proarrhythmic effects of cisapride (Propulsid): High affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 417:1 (1997), 28–32.
27. [27] Drolet, B., Rousseau, G., Daleau, P., Cardinal, R., Turgeon, J., Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation 102:16 (2000), 1883–1885.
28. [28] De Bruin, M.L., Langendijk, P.N.J., Koopmans, R.P., Wilde, A.A.M., Leufkens, H.G.M., Hoes, A.W., In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs. Br J Clin Pharmacol 63:2 (2007), 216–223.
29. [29] Domperidone: ventricular arrhythmia and sudden death (continued). Prescrire Int, 21(129), 2012, 183.
30. [30] Noord van, C., Dieleman, J.P., Herpen van, G., Verhamme, K., Sturkenboom fessor D iriam CJM, Domperidone and ventricular arrhythmia or sudden cardiac death. Drug Saf 33:11 (2010), 1003–1014.
31. [31] Chou, C.C., Wu, D., Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block. Chang Gung Med J 24:12 (2001), 805–809.
32. [32] Crumb, W.J., Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions. J Pharmacol Exp Ther 292:1 (2000), 261–264.
33. [33] Hancox, J.C., McPate, M.J., El Harchi, A., Zhang, Y.H., The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol Ther 119:2 (2008), 118–132.
34. [34] Drolet, B., Zhang, S., Deschênes, D., Rail, J., Nadeau, S., Zhou, Z., et al. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J Cardiovasc Electrophysiol 10:12 (1999), 1597–1604.
35. [35] Lu, H.R., Vlaminckx, E., Hermans, A.N., Rohrbacher, J., Van Ammel, K., Towart, R., et al. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. Br J Pharmacol 154:7 (2008), 1427–1438.
36. [36] Sweetman, S., Métopimazine. Martindale: the complet drug reference, 37th edition, 2011, Pharmaceutical Press, London.
37. [37] Kuryshev, Y.A., Brown, A.M., Wang, L., Benedict, C.R., Rampe, D., Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther 295:2 (2000), 614–620.
38. [38] Charbit, B., Albaladejo, P., Funck-Brentano, C., Legrand, M., Samain, E., Marty, J., Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology 102:6 (2005), 1094–1100.
39. [39] Freedman, S.B., Uleryk, E., Rumantir, M., Finkelstein, Y., Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med, 64(1), 2014 19–25.e6.
40. [40] Jo, S.-H., Hong, H.-K., Chong, S.H., Lee, H.S., Choe, H., H1 antihistamine drug promethazine directly blocks hERG K+ channel. Pharmacol Res 60:5 (2009), 429–437.
41. [41] Bégaud, B., Martin, K., Haramburu, F., Moore, N., Rates of spontaneous reporting of adverse drug reactions in France. JAMA, 288(13), 2002, 1588.